NCT05398081View on ClinicalTrials.gov

Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

February 6, 2022

Study Completion Date

March 5, 2022

Conditions
Surgical Site InfectionAntibiotics Prophylaxis
Interventions
DRUG

Cefuroxime (Zinnat®)

Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used

DRUG

Ceftriaxone (Rocephin®)

Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used

Trial Locations (1)

5116

University College Hospital, Ibadan

All Listed Sponsors
lead

Dr. Promise Tamunoipiriala Jaja

OTHER

NCT05398081 - Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery | Biotech Hunter | Biotech Hunter